P411: Early ultrasound assessment predicts therapy response: an easy tool for clinical decision makingECCO’23 CopenhagenYear: 2023
Authors: CalabresePhD, E.(1)*;Castiglione, F.(2);De Cristofaro, E.(1);Rispo, A.(2);Capacchione , C.(1);Testa, A.(2);Guarino, A.D.(2);Caiazzo, A.(2);Monteleone, G.(1);Zorzi, F.(1);
(1)University of Rome Tor Vergata, Gastroenterology Unit- Department of Systems Medicine, Rome, Italy;(2)Federico II- School of Medicine- Naples- Italy, Gastroenterology- Department of Clinical Medicine and Surgery, Naples, Italy;
P412: Time trend in clinicopathological features and prognosis of Ulcerative Colitis associated neoplasia: A nationwide cohort in JapanECCO’23 CopenhagenYear: 2023
Authors: Komatsu, K.(1)*;Shinagawa, T.(1);Noguchi, T.(1);Uchino, M.(2);Ikeuchi, H.(2);Okabayashi, K.(3);Tanaka, S.(4);Futami, K.(5);Itabashi, M.(6);Watanabe, K.(7);Nagahara, H.(8);Okita, Y.(9);Shimada, Y.(10);Mizuuchi, Y.(11);Okamoto, K.(12);Yamada, K.(13);Sato, Y.(14);Mizushima, T.(15);Kimura, H.(16);Takahashi, K.(17);Hida, K.(18);Kinugasa, Y.(19);Ishida, F.(20);Okuda, J.(21);Daito, K.(22);Yamamoto, T.(23);Yamamoto, S.(24);Koyama, F.(25);Hanai, T.(26);Komori, K.(27);Shida, D.(28);Arakaki, J.(29);Akagi, Y.(30);Yamaguchi, S.(31);Ueno, H.(32);Matsuda, K.(33);Ajioka, Y.(34);Sugihara, K.(35);Ishihara, S.(1);
(1)The University of Tokyo, Department of Surgical Oncology, Tokyo, Japan;(2)Hyogo College of Medicine, Department of Inflammatory Bowel Disease Surgery, Nishinomiya, Japan;(3)Keio University School of Medicine, Department of Surgery, Tokyo, Japan;(4)Hiroshima University Hospital, Department of Endoscopy, Hiroshima, Japan;(5)Fukuoka University Chikushi Hospital, Department of Surgery, Chikushino, Japan;(6)Tokyo Women's Medical University, Department of Surgery- Division of Inflammatory Bowel Disease Surgery, Tokyo, Japan;(7)Tohoku University Graduate School of Medicine, Department of Surgery, Sendai, Japan;(8)Osaka City University Graduate School of Medicine, Department of Gastroenterological Surgery, Osaka, Japan;(9)Mie University Graduate School of Medicine, Department of Gastrointestinal and Pediatric Surgery- Institute of Life Sciences, Mie, Japan;(10)Niigata University, Division of Digestive and General Surgery- Graduate School of Medical and Dental Sciences, Niigata, Japan;(11)Kyushu University, Department of Surgery and Oncology- Graduate School of Medical Sciences, Fukuoka, Japan;(12)Tokyo Yamate Medical Center, Department of Coloproctology, Tokyo, Japan;(13)Coloproctology Center Takano Hospital, Department of Surgery, Kumamoto, Japan;(14)Toho University Sakura Medical Center, Department of Surgery, Chiba, Japan;(15)Osaka University, Department of Gastroenterological Surgery- Graduate School of Medical, Osaka, Japan;(16)Yokohama City University Medical Center, Inflammatory Bowel Disease Center, Yokohama, Japan;(17)Tohoku Rosai Hospital, Department of Colorectal Surgery, Sendai, Japan;(18)Kyoto University Hospital, Department of Surgery-, Kyoto, Japan;(19)Tokyo Medical and Dental University, Department of Gastrointestinal Surgery, Tokyo, Japan;(20)Showa University Northern Yokohama Hospital, Digestive disease center, Kanagawa, Japan;(21)Osaka Medical and Pharmaceutical University, Department of General and Gastroenterological Surgery, Takatsuki, Japan;(22)Kindai University, Department of Surgery- Faculty of Medicine, Osaka, Japan;(23)Yokkaichi Hazu Medical Center, Inflammatory Bowel Disease Center, Yokkaichi, Japan;(24)Tokai University School of Medicine, Department of Gastroenterological Surgery, Tokyo, Japan;(25)Nara Medical University, Department of Surgery, Nara, Japan;(26)Fujita Health University- School of Medicine, Department of Surgery, Mie, Japan;(27)Aichi Cancer Center Hospital, Department of Gastroenterological Surgery, Aichi, Japan;(28)IMSUT Hospital- The Institute of Medical Science- The University of Tokyo, Department of Surgery, Tokyo, Japan;(29)Urasoe General Hospital, Center for Gastroenterology- Department of Surgery, Okinawa, Japan;(30)Kurume University Hospital, Department of Surgery, Kurume, Japan;(31)Saitama Medical University International Medical Center-, Department of Gastroenterological Surgery, Saitama, Japan;(32)National Defense Medical College, Department of Surgery, Tokorozawa, Japan;(33)Teikyo University School of Medicine, Department of Surgery, Tokyo, Japan;(34)Niigata University, Department of Pathology, Niigata, Japan;(35)Tokyo Medical and Dental University, Honorary Director, Tokyo, Japan;The Study Group for Inflammatory Bowel Disease Associated Intestinal Cancers by the Japanese Society for Cancer of the Colon and Rectum
P413: Withdrawal versus continuation of thiopurine in vedolizumab-treated patients with Ulcerative Colitis (VIEWS): a multi-centre randomised controlled trialECCO’23 CopenhagenYear: 2023
Authors: Pudipeddi, A.(1)*;Paramsothy, S.(1);Kariyawasam, V.(2);Paramsothy, R.(2);Ghaly, S.(3);Haifer, C.(3);An, Y.K.(4);Begun, J.(4);Connor, S.(5);Corte, C.(6);Ward, M.(7);De Cruz, P.(8);Fung, C.(9);Redmond, D.(1);Leong, R.W.(1);
(1)Concord Repatriation General Hospital, Department of Gastroenterology and Hepatology, Sydney, Australia;(2)Blacktown Hospital, Department of Gastroenterology, Sydney, Australia;(3)St Vincent's Hospital, Department of Gastroenterology, Sydney, Australia;(4)Mater Hospital, Department of Gastroenterology, Brisbane, Australia;(5)Liverpool Hospital, Department of Gastroenterology, Sydney, Australia;(6)Royal Prince Alfred Hospital, AW Morrow Gastroenterology and Liver Centre, Sydney, Australia;(7)The Alfred Hospital, Department of Gastroenterology, Melbourne, Australia;(8)Austin Hospital, Department of Gastroenterology, Melbourne, Australia;(9)Concord Repatriation General Hospital, Department of Anatomical Pathology, Sydney, Australia;
P414: Comparative real-world effectiveness and persistence of vedolizumab versus anti-TNF therapy in biologic-naïve patients with Crohn´s disease with propensity score adjustment: two-year maintenance phase results from the prospective VEDO-IBD studyECCO’23 CopenhagenYear: 2023
Authors: Bokemeyer, B.(1,2,3)*;Plachta-Danielzik, S.(3);Efken, P.(4);Mohl, W.(5);Hoffstadt, M.(6);Krause, T.(7);Schweitzer, A.(8);Schnoy, E.(9);Atreya, R.(10);Teich, N.(11);Trentmann, L.(12);Ehehalt, R.(13);Franzenburg, S.(3);Hartmann, P.(4);di Giuseppe, R.(3);Schreiber, S.(2,3);
(1)Interdisciplinary Crohn Colitis Centre Minden, Crohn Colitis Centre, Minden, Germany;(2)University Hospital Schleswig-Holstein- Campus Kiel, Clinic of General Internal Medicine I, Kiel, Germany;(3)Competence network IBD, Study department, Kiel, Germany;(4)Gastroenterology Practice Minden, Practice, Minden, Germany;(5)Center for Gastroenterology Saar MVZ, Practice, Saarbruecken, Germany;(6)Gastroenterology Practice Iserlohn, Practice, Iserlohn, Germany;(7)Gastroenterology Practice Kassel, Practice, Kassel, Germany;(8)Gastroenterology Practice Muenster, Practice, Muenster, Germany;(9)University Hospital Augsburg, III. medical clinic, Augsburg, Germany;(10)Friedrich-Alexander-University Erlangen-Nuernberg, Medical Clinic 1, Erlangen, Germany;(11)Gastroenterology Practice Leipzig, Practice, Leipzig, Germany;(12)Gastroenterology Practice Bremen, Practice, Bremen, Germany;(13)Gastroenterology Practice Heidelberg, Practice, Heidelberg, Germany;
P415: Real-world data in Inflammatory Bowel Diseases on vedolizumab therapy: Interim analysis of the non-interventional LISTEN II studyECCO’23 CopenhagenYear: 2023
Authors: Stallmach, A.(1)*;Schulze, H.(2);Teich, N.(3);Cavlar, T.(4);Jana, K.(4);Henneberger, S.(5);
(1)University Hospital Jena, Clinic for Internal Medicine IV, Jena, Germany;(2)AGAPLESION Markus-Hospital, Medical Clinic I, Frankfurt am Main, Germany;(3)Group Practice in Internal Medicine for Digestive and Metabolic Diseases, Group Practice in Internal Medicine for Digestive and Metabolic Diseases, Leipzig, Germany;(4)Takeda Pharma Vertrieb GmbH & Co. KG, Medical Department, Berlin, Germany;(5)Institut Dr. Schauerte GmbH, Project Management, Munich, Germany;
P416: The impact of remission on healthcare resource utilisation and costs amongst patients with inflammatory bowel disease in France, Germany, Italy, Spain, and the United Kingdom.ECCO’23 CopenhagenYear: 2023
Authors: Patel, K.V.(1)*;Salmon, P.(2);Marin-Jiménez, I.(3);Thessen, M.(4);Kligys, K.(4);Sharma, D.(4);Sanchez Gonzalez, Y.(4);Kershaw, J.(5);
(1)NHS Foundation Trust, St George's University Hospital, London, United Kingdom;(2)Adelphi Real World, n/a, Bollington, United Kingdom;(3)Hospital General Universitario Gregorio Marañón, n/a, Madrid, Spain;(4)AbbVie Inc, n/a, North Chicago, United States;(5)Adelphi Real World, n/a, Bollington, United States;
P417: Frequent Early Nocebo Complaints but Maintained Clinical Efficacy, Biomarker and Therapeutic drug levels following mandatory Biosimilar Switch in Patients with Inflammatory Bowel disease: Preliminary data from a Prospective Observational Cohort StudyECCO’23 CopenhagenYear: 2023
Authors: Wetwittayakhlang, P.(1)*;Karkout, K.(2);Tselekouni, P.(1);Aljabri, R.(1);Bessissow, T.(1);Afif, W.(1);Wild, G.(1);Bitton, A.(1);LakatosPhD, P.L.(3,4);
(1)McGill University Health Centre, Division of Gastroenterology and Hepatology, Montreal, Canada;(2)McGill University Health Centre, Department of Internal Medicine, Montreal, Canada;(3)Mcgill University Health Center, IBD Centre, Montréal, Canada;(4)Semmelweis University, Department of Internal Medicine and Oncology, Budapest, Hungary;
P418: Dose escalation of oral 5-aminosalicylic acid for ulcerative colitis with Mayo endoscopic subscore of one improves long-term prognosis: a one-year multicentre, open-label, randomized controlled trial.ECCO’23 CopenhagenYear: 2023
Authors: Aoki, Y.(1)*;Fukuda, T.(1,2,3);Kiyohara, H.(1,2);Yokoyama, A.(4);Nakazawa, A.(4);Yoshimatsu, Y.(1);Sugimoto, S.(1);Nanki, K.(1);Mikami, Y.(1);Fukuhara, K.(5);Mizuno, S.(1);Sujino, T.(6);Mutaguchi, M.(6);Takabayashi, K.(6);Morohoshi, Y.(3);Hosoda, Y.(7);Ogata, H.(6);Iwao, Y.(5);Naganuma, M.(1,8);Kanai, T.(1);
(1)Keio University School of Medicine, Division of Gastroenterology and Hepatology- Department of Internal Medicine, Tokyo, Japan;(2)Kitasato University Kitasato Institute Hospital, Center for Advanced IBD Research and Treatment, Tokyo, Japan;(3)Yokohama Municipal Citizen's Hospital, Department of Gastroenterology, Yokohama, Japan;(4)Tokyo Saiseikai Central Hospital, Department of Gastroenterology, Tokyo, Japan;(5)Keio University School of Medicine, Center for Preventive Medicine, Tokyo, Japan;(6)Keio University School of Medicine, Center for Diagnostic and Therapeutic Endoscopy, Tokyo, Japan;(7)National Hospital Organization Saitama Hospital, Department of Gastroenterology, Wako, Japan;(8)Kansai Medical University, Third Department of Internal Medicine- Division of Gastroenterology and Hepatology, Hirakata, Japan;
P419: Outcomes at one year after sequential use of high-dose tofacitinib following infliximab in Acute Severe Ulcerative ColitisECCO’23 CopenhagenYear: 2023
Authors: Eqbal, A.(1)*;Hilley, P.(1);Gilmore, R.(1);Li Wai Suen, C.(1);Choy, M.(1,2);De Cruz, P.(1,2);
(1)Austin health, Gastroenterology, Melbourne, Australia;(2)The University of Melbourne- Austin Academic Centre, Medicine, Melbourne, Australia;
P420: Safety & feasibility of targeted mesenteric approaches to ileocolic resection and anastomosis in Crohn's DiseaseECCO’23 CopenhagenYear: 2023
Authors: Holubar, S.(1)*;Cohen, B.(2);Uchino, T.(1);Lincango, E.(1);Prien, C.(1);Joseph, A.(2);Achkar, J.P.(2);Gunter, R.(1);Lashner, B.(2);DeLaney, C.(3);Ban, K.(1);Bolshinsky, V.(1);Lipman, J.(1);Liska, D.(1);Philpott, J.(2);Naseer, M.(2);Kanters, A.(1);Braga-Neto, M.(2);Rieder, F.(2);Somovilla, J.(1);Qazi, T.(2);Regueiro, M.(2);Hull, T.(1);Steele, S.(1);
(1)Cleveland Clinic Foundation, Department of Colorectal Surgery, Cleveland, United States;(2)Cleveland Clinic Foundation, Digestive Disease and Surgery Institute, Cleveland, United States;(3)Cleveland Clinic Florida, Department of Colorectal Surgery, Florida, United States;
P421: Real-world effectiveness and safety of vedolizumab induction therapy for Crohn's disease in Poland – a prospective, observational POLONEZ II study considering patient-reported outcomesECCO’23 CopenhagenYear: 2023
Authors: Liebert, A.(1);Kłopocka, M.(1);Cichoż-Lach, H.(2);Michalak, A.(2);Talar-Wojnarowska, R.(3);Domżał-Magrowska, D.(3);Filipiuk, A.(4);Krogulecki, M.(4);Kopertowska-Majchrzak, M.(5);Eder, P.(6);Stawczyk-Eder, K.(6);Waszak, K.(6);Zagórowicz, E.(7,8);Wojciechowski, K.(9,10);Drygała, S.(9)*;
(1)Collegium Medicum in Bydgoszcz- Nicolaus Copernicus University in Toruń, Department of Gastroenterology and Nutritional Disorders, Bydgoszcz, Poland;(2)Medical University of Lublin, Department of Gastroenterology, Lublin, Poland;(3)Medical University of Lodz, Department of Digestive Tract Diseases, Łódź, Poland;(4)Military Institute of Medicine, Department of Gastroenterology, Warsaw, Poland;(5)General Hospital, Department of Internal Diseases, Międzychód, Poland;(6)Poznan University of Medical Sciences- H. Święcicki University Hospital, Department of Gastroenterology- Dietetics- and Internal Diseases, Poznań, Poland;(7)The Maria Sklodowska-Curie National Research Institute of Oncology, Department of Gastroenterology, Warsaw, Poland;(8)The Medical Center of Postgraduate Education, Department of Gastroenterology- Hepatology and Clinical Oncology, Warsaw, Poland;(9)Takeda Pharma sp. z o.o., Medical Affairs, Warsaw, Poland;(10)Independent Public Health Care Center, Department of Internal Diseases, Tarczyn, Poland;
P423: Effect of tofacitinib on colectomy risk in anti TNF-alfa refractory ulcerative colitisECCO’23 CopenhagenYear: 2023
Authors: Romeo, S.(1)*;Carvalhas Gabrielli, A.M.(1);Ferretti, F.(2);Piazza O Sed, N.(3);Mazzola, A.M.(4);Alicante, S.(1);Berté, R.(1);Scribano, M.L.(5);Buscarini, E.(1);Ricci, C.(4);Caprioli, F.(3,6);Ardizzone, S.(2);Cannatelli, R.(2);
(1)ASST Ospedale Maggiore, Gastroenterology and Digestive Endoscopy Department, Crema, Italy;(2)ASST Fatebenefratelli-Sacco, Gastroenterology Unit - Department of Biomedical and Clinical Sciences- University of Milan, Milan, Italy;(3)Fondazione IRCCS Cà Granda- Ospedale Maggiore Policlinico di Milano, Gastroenterology and Endoscopy Unit, Milan, Italy;(4)Spedali Civili di Brescia, Gastroenterology Unit- Università di Brescia, Brescia, Italy;(5)Villa Stuart Multi-Speciality Clinic, Villa Stuart Multi-Speciality Clinic, Rome, Italy;(6)Università degli Studi di Milano, Department of Pathophysiology and Transplantation, Milan, Italy;
P424: Do antiTNF through levels correlate with joint extraintestinal manifestations (EIM) activity in Inflammatory bowel disease (IBD) patients?ECCO’23 CopenhagenYear: 2023
Authors: Madero Velázquez, L.(1)*;Jovani, V.(2);Andrés, M.(3);Más, P.(4);Aguas, M.(5);Vicens, E.(6);Ojeda, A.(7);Noguera-Pons, J.R.(8);Ranieri, L.(9);Zabana, Y.(10);Pujol, M.(11);Barreiro de Acosta, M.(12);Pérez-Pampin, E.(13);Bernal, L.(14);Belen, O.(14);Moreno, V.(14);García, M.F.(15);Sempere, L.(1);Zapater, P.(16);Gutiérrez Casbas, A.(17);
(1)Hospital General Universitario Dr Balmis de Alicante- ISABIAL, Gastroenterology, Alicante, Spain;(2)Hospital General Universitario Dr Balmis de Alicante- ISABIAL, Reumatology, Alicante, Spain;(3)Hospital General Universitario Dr Balmis de Alicante- ISABIAL- Departamento Medicina Clínica Universidad Miguel Hernández, Reumatology, Alicante, Spain;(4)Hospital General Universitario Dr Balmis de Alicante- ISABIAL, Farmacia hospitalaria, Alicante, Spain;(5)Hospital Policlínico Universitario La Fé, Gastroenterology, Valencia, Spain;(6)Hospital Policlínico Universitario La Fé, Reumatology, Valencia, Spain;(7)Hospital General Universitario Elche, Gastroenterology, Alicante, Spain;(8)Hospital General Universitario de Elche, Reumatology, Alicante, Spain;(9)Hospital Vinalopó, Reumatology, Elche, Spain;(10)Hospital Universitari Mútua Terrassa. CIBERehd, Gastroenterology, Barcelona, Spain;(11)Hospital Universitari Mútua Terrassa, Reumatology, Barcelona, Spain;(12)Hospital Clínico Universitario de Santiago de Compostela. Universidad De Santiago de Compostela, Gastroenterology, Santiago de Compostela, Spain;(13)Hospital Clínico Universitario de Santiago de Compostela, Reumatology, Santiago de Compostela, Spain;(14)Hospital General Universitario Dr Balmis de Alicante, Gastroenterology, Alicante, Spain;(15)Hospital General Universitario de Elche, Gastroenterology, Alicante, Spain;(16)Hospital General Universitario Dr Balmis de Alicante- ISABIAL. Universidad Miguel Hernández- IDiBE-CIBERehd, Clinical Pharmacology, Alicante, Spain;(17)Hospital General Universitario Dr Balmis de Alicante- ISABIAL. CIBERehd, Gastroenterology, Alicante, Spain;
P425: The utility of intestinal ultrasound to inform clinical decision makingECCO’23 CopenhagenYear: 2023
Authors: Yeaman, F.(1)*;Panaccione, R.(1);Ma, C.(1);Lu, C.(1);Seow, C.(1);Kaplan, G.(1);Maracle, B.(1);Novak, K.(1);
(1)University of Calgary- Foothills Medical Centre, Gastroenterology and Hepatology, Calgary, Canada;
P426: Sex and sexuality in IBD - the pediatric gastroenterologists' point of viewECCO’23 CopenhagenYear: 2023
Authors: Anafy, A.(1,2);Cohen, S.(1,2);Matar, M.(3);Shouval, D.S.(2,3);Shamir, R.(2,3);Weintraub, Y.(2,3)*;
(1)Dana-Dwek Children's Hospital- Tel Aviv Sourasky Tel-Aviv Medical Center, Pediatric Gastroenterology Institute, Tel Aviv, Israel;(2)Tel Aviv University, Sackler School of Medicine, Tel Aviv, Israel;(3)Schneider Children's Medical Center of Israel, Institute of Gastroenterology- Nutrition and Liver Diseases, Petach Tikva, Israel;
P427: One Year Follow up of Three Phase IB/IIA Clinical Trials of Ex Vivo Expanded Allogeneic Bone Marrow Derived Mesenchymal Stem Cells for the Treatment of Fistulizing Crohn's DiseaseECCO’23 CopenhagenYear: 2023
Authors: Lightner, A.(1)*;Otero Pineiro MD , A.(2);Reese, J.(3);Ream, J.(4);Nachand, D.(4);Obi, M.(2);Adams, A.(2);VanDenBossche , A.(2);Dadgar, N.(2);Hull, T.(2);
(1)Cleveland Clinic, Department of Colorectal Surgery, Cleveland, United States;(2)Cleveland Clinic, Colorectal Surgery, Cleveland, United States;(3)Case Western University, Regenerative Medicine, Cleveland, United States;(4)Cleveland Clinic, Radiology, Cleveland, United States;
P428: Pharmacist led clinic in Inflammatory Bowel DiseaseECCO’23 CopenhagenYear: 2023
Authors: Kwok, J.(1)*;Smith, J.(2);Gashau, W.(2);Shuttleworth, E.(2);
(1)Lancashire Teaching Hospitals NHS Foundation Trust, Pharmacy, Preston, United Kingdom;(2)Lancashire Teaching Hospitals NHS Foundation Trust, Gastroenterology, Preston, United Kingdom;
P429: Patient skeletal muscle area and postoperative clinical recurrence in Crohn's disease: a retrospective studyECCO’23 CopenhagenYear: 2023
Authors: Inniss, S.(1,2)*;Simpson, K.(1);Fragkos, K.(1);Wood, C.(1);Smith, A.(2);Rahman, F.(1,2);
(1)University College London Hospitals NHS Foundation Trust, Gastrointestinal Services, London, United Kingdom;(2)University College London, Eastman Dental Institute, London, United Kingdom;
P430: Mesalazine dose modification based on fecal calprotectin levels in ulcerative colitis patients in clinical remissionECCO’23 CopenhagenYear: 2023
Authors: Piñero, G.S.(1,2,3)*;Mañosa , M.(1,3);Cañete, F.(1,3);Calafat, M.(1,3);González, L.(1,3);Ruffinengo, O.(2);Domènech, E.(1,3);
(1)Hospital Universitari Germans Trias i Pujol, Gastroenterology, Badalona, Spain;(2)Hospital Provincial del Centenario, Gastroenterology, Rosario, Argentina;(3)CiberEHD, Gastroenterology, Madrid, Spain;
